When asked what they’d like for Christmas, many aging adults respond with, “Don’t get me anything — I don’t need more things.

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line[1] Data ...

Xu, W. , Xing, X. and Cheng, S. (2025) Urine-Based Liquid Biopsy for Detecting Recurrence of Bladder Cancer. International ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 ...

The IDEXX Cancer Dx is a new blood-based screening/diagnostic panel aimed at detecting canine lymphoma from serum or whole ...

Also known as "blue field entoptic phenomenon" and "blue sky sprites", the little dots move in time with your heartbeat.

(NAPSI)—If you’ve ever dealt with acute pain, whether from a sports injury, a sudden sprain, or everyday strain, you know how ...

Comparing the genomes of snakes with distinct coloration patterns pinpointed the genetic variants that contribute to these ...

The Society of Urologic Oncology (SUO) and Ferring Pharmaceuticals today announced the SUO NMIBC (non-muscle invasive bladder ...